Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL638667 | 0.82 | TP53 (0.41) | SMN1; SMN2TSHRTP53 | |
| SCHEMBL29929218 | 0.82 | TP53 (0.41) | SMN1; SMN2TSHRTP53 | |
| SCHEMBL27701066 | 0.80 | TP53 (0.39) | SMN1; SMN2TSHRTP53 | |
| SCHEMBL9844828 | 0.80 | CCR2 (0.32) | NPC1HPGDRAB9ASMN1; SMN2TP53 | |
| SCHEMBL9947629 | 0.78 | CYP3A4 (0.36) | FLT1FLT4KDRNPC1RAB9A | |
| SCHEMBL11021176 | 0.78 | RAB9A (0.31) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11110746 | 0.78 | RAB9A (0.31) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30739512 | 0.78 | TP53 (0.41) | SMN1; SMN2TSHRTP53 | |
| SCHEMBL4067475 | 0.78 | CYP3A4 (0.32) | TSHRTP53 | |
| SCHEMBL9745484 | 0.78 | TP53 (0.41) | SMN1; SMN2TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363624-A2 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020156120-A1 | Fluoro oxindole derivatives as modulators of KCNQ potassium channels | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6469042-B1 | ANALGESICS FOR MIGRAINES | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-22 | — | — | US | disclosed |
| WO-2002066426-A2 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156120-A1 | Fluoro oxindole derivatives as modulators of KCNQ potassium channels | KCNQ1, KCNQ2, KCNQ3 | FLT1 2631/4885FLT4 2308/4885KDR 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.